Status:

COMPLETED

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Carcinoid Tumor

Malignant Carcinoid Syndrome

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in pati...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Advanced (unresectable or metastatic) carcinoid tumor
  • Confirmed low-grade or intermediate-grade neuroendocrine carcinoma
  • Documented progression of disease within 12 months prior to randomization.
  • Measurable disease determined by triphasic computer tomography (CT) scan or magnetic resonance imaging (MRI).
  • Exclusion criteria:
  • Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.
  • Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment.
  • Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus, temsirolimus, everolimus)
  • Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.
  • Severe or uncontrolled medical conditions
  • Chronic treatment with corticosteroids or other immunosuppressive agent.
  • Other primary cancer within 3 years.
  • Other protocol-defined inclusion/exclusion criteria applied

Exclusion

    Key Trial Info

    Start Date :

    December 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2013

    Estimated Enrollment :

    429 Patients enrolled

    Trial Details

    Trial ID

    NCT00412061

    Start Date

    December 1 2006

    End Date

    June 1 2013

    Last Update

    November 21 2014

    Active Locations (70)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 18 (70 locations)

    1

    University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2)

    Tucson, Arizona, United States, 85719

    2

    Highlands Oncology Group The Center for Chest Care

    Fayetteville, Arkansas, United States, 72703

    3

    Hematology Oncology Services of Arkansas

    Little Rock, Arkansas, United States, 72205

    4

    Pacific Cancer Medical Center, Inc.

    Anaheim, California, United States, 92801